The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.
  Year-End Report 17/18, October 2, 2019

Dear Shareholders and readers

We systematically build our value proposition around intralymphatic administration of Diamyd®. The clinical results from DIAGNODE-1 provide proof of concept of a strong, clinically relevant effect for preserving the patient’s own insulin production. Moreover, immunological results indicate a response as in immunological tolerance. In addition, a recently published feasibility study based on interviews and questionnaires highlighted the ease of use for intralymphatic injections...

With Diamyd® in late stage development - the world’s furthest advanced antigen-specific diabetes therapeutic, Remygen® in early clinical phase, and a strong IP position, we look forward to further strengthening our value proposition during the forthcoming year.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
October 31, 2019
Annual Report
Annual Report 2018/2019
November 4, 2019
Stora Aktiedagen
Event by Aktiespararna, Gothenburg, Sweden.
November 21, 2019
Annual General Meeting
Annual General Meeting 2018/2019
January 22, 2020
Quarterly Report I
Quarterly Report 1 2019/2020
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of September 30, 2019

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 2 556 223 7 333 040 14.30 35.69
Avanza Pension 9 117 086 13.18 9.89
Lindkvist, Bertil 6 200 000 8.96 6.73
Nordnet Pension 2 326 797 3.36 2.52
Hansen, Patrik 1 700 000 2.46 1.84
Swedbank Försäkring 1 047 412 1.51 1.14
Konstruktions o Försäljningsaktiebolag 750 000 1.08 0.81
Arandi Development AB 500 000 0.72 0.54
Relbo AB 475 550 0.69 0.52
Schelé, Sven 460 000 0.67 0.50
Remaining shareholders 36 703 688 53.1 39.8
Total 2 556 223 66 613 573 100.0 100.0

Error: Object reference not set to an instance of an object.